Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Citi
Fuji
AstraZeneca
Argus Health
Cipla
Dow
Merck
US Army

Generated: April 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,732,058

« Back to Dashboard

Title:2-(2,4,5-substituted-anilino)pyrimidine compounds
Abstract: The present invention relates to certain 2-(2,4,5-substituted-anilino)pyrimidine compounds and pharmaceutically acceptable salts thereof which may be useful in the treatment or prevention of a disease or medical condition mediated through certain mutated forms of epidermal growth factor receptor (for example the L858R activating mutant, the Exon19 deletion activating mutant and the T790M resistance mutant). Such compounds and salts thereof may be useful in the treatment or prevention of a number of different cancers. The invention also relates to pharmaceutical compositions comprising such compounds and salts thereof, especially useful polymorphic forms of these compounds and salts, intermediates useful in the manufacture of such compounds and to methods of treatment of diseases mediated by various different forms of EGFR using such compounds and salts thereof.
Inventor(s): Butterworth; Sam (Macclesfield, GB), Finlay; Maurice Raymond Verschoyle (Macclesfield, GB), Ward; Richard Andrew (Macclesfield, GB), Redfearn; Heather Marie (Macclesfield, GB)
Assignee: ASTRAZENECA AB (SE)
Filing Date:Dec 19, 2014
Application Number:14/576,721
Claims:1. A compound of Formula (I) ##STR00023## or a pharmaceutically acceptable salt thereof, wherein: G is 1H-indol-3-yl or 1-methyl-1H-indol-3-yl; R.sup.1 is hydrogen; R.sup.2 is methoxy; and R.sup.3 is [2-(dimethylamino)ethyl](methyl)amino or [2-(methylamino)ethyl](methyl)amino.

2. The compound of Formula (I) as claimed in claim 1 which is: N-(2-[2-dimethylaminoethyl-methylamino]-5-{[4-(1H-indol-3-yl)pyrimidin-2-- yl]amino}-4-methoxyphenyl)-prop-2-enamide or a pharmaceutically acceptable salt thereof.

3. The compound of Formula (I) as claimed in claim 1 which is: N-(4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}-2-[methyl-(2- -methylaminoethyl)amino]-phenyl)prop-2-enamide or a pharmaceutically acceptable salt thereof.

4. A pharmaceutical composition comprising a compound of Formula (I) as claimed in any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically-acceptable diluent or carrier.

5. A method for treating lung cancer in a warm-blooded animal in need of such treatment, which comprises administering to said animal an effective amount of the compound of Formula (I) as claimed in any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof.

6. The method of claim 5, wherein the lung cancer is non-small cell lung cancer.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Chubb
Fuji
AstraZeneca
Healthtrust
McKinsey
Moodys
Farmers Insurance
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.